Introduction
Despite efficient vaccines, measles continues to cause considerable morbidity and mortality worldwide. Improved vaccination strategies may well be required to achieve the World Health Organization goal of measles eradication (Nokes & Cutts, 1993) . Current live-attenuated vaccines require expensive cold-chains and lack resistance to transplacentally acquired maternal antibodies. Subunit vaccines based on peptides would be stable under tropical conditions and would potentially be resistant to maternal antibodies (Albrecht et al., 1977 ; . The potential of peptides for immunizing against morbilliviruses has been Author for correspondence : Claude P. Muller. demonstrated by M. W. Steward and colleagues (Obeid et al., 1995) . Although the fusion protein can be the target of neutralizing antibodies (Malvoisin & Wild, 1990) , most of the protective activity of measles virus (MV) antibodies is directed against the haemagglutinin protein (MV-H ; Giraudon & Wild, 1985) . Therefore, protective B cell epitopes of MV-H would be important components of such a subunit vaccine. Various strategies have been used to map antigenic sites of the MV-H protein (Sheshberadaran & Norrby, 1986 ; Carter et al., 1982 ; Hu et al., 1993 ; Liebert et al., 1994 ; Hummel & Bellini, 1995 ; Ma$ kela$ et al., 1987 ; Muller et al., 1993) . Most of these techniques, however, did not discriminate between linear and conformational epitopes, or did not associate functional activities with epitopes. Neutralizing linear sites of the MV-H protein have been identified using monoclonal antibodies (MAbs) Ziegler et al., 1996) or anti-peptide antisera (Ma$ kela$ et al., 1989 b) . In the present study, we have developed MAbs which protect against lethal challenge with rodent-adapted measles virus and which recognize a defined linear site. They seem to define a topographically and functionally distinct interface of the H protein.
Methods
Monoclonal antibodies. MAbs (BH1, BH47, BH59, BH103, BH129 ; numbers designate sequential clones) were derived from mice immunized with affinity-purified Edmonston B strain MV inactivated with propiolactone, as described (Fournier et al., 1996 ; Ziegler et al., 1996) . Concentrations of the affinity-purified MAbs were determined as absorbance (A) at 280 nm. The above MAbs were all of the IgG1 subclass as determined with a commercial kit (Hycult Biotechnology). Western blots were done with concentrated virus, purified by sucrose gradient centrifugation (Fournier et al., 1996) .
Peptides. Synthesis of 121 biotinylated pentadecapeptides overlapping by 10 amino acids and covering the whole sequence of the MV-H protein (Edmonston strain ; Alkhatib & Briedis, 1986) and synthesis of free truncation-analogues of peptides H236-250 and H241-255 were performed by simultaneous multiple-peptide synthesis as described (Wiesmu$ ller et al., 1992 ; Ziegler et al., 1996) . Biotinylated peptides were modified C-terminally by two ε-amino caproic acid residues and one lysine residue which separate the peptide from the biotin coupled to the Nε-amino group of lysine amide. ELISAs and competition ELISAs based on the biotinylated peptides were as described (Fournier et al., 1996 ; Ziegler et al., 1996) .
MV-ELISA.
MV-specific antibodies were detected using either an ELISA based on immobilized MV concentrate (Fournier et al., 1996) or a commercial certified ELISA based on permanent monkey kidney cells (Enzygnost ; a kind gift of Dr Giesendorf, Behringwerke, Marburg, Germany).
Functional assays. Neutralization inhibition (NT) was measured in the presence of MAbs using an early passage of MV Edmonston strain (ATCC VR-24) grown on Vero cells as described previously (Norrby & Gollmar, 1972 ; Muller et al., 1995) . Haemagglutination inhibition assays (HI) and haemolysis inhibition (HLI) were measured in a combined assay as described previously (Norrby & Gollmar, 1972 Orvell, 1976) . In brief, 100 µl of MAb was incubated for 1 h at 22 mC with an equal volume of MV in a V-bottom microtitre plate ; 50 µl of a 10 % suspension of washed African Green monkey (Cercopithecus aethiops ; RIVM, Bilthoven, The Netherlands) erythrocytes was added and incubated for 3 h at 37 mC. After low speed centrifugation, lysis was assessed in the supernatant as A &%! . For the rosette forming assay, 10& Ltk − cells transfected with H (Ltk − H ; kindly provided by Drs Wild and Beauverger, Lyon, France ; Beauverger et al., 1993 Beauverger et al., , 1994 were incubated for 1 h at 4 mC with 200 µl of diluted MAbs. Monkey erythrocytes were then added to a final concentration of 0n1 % and incubated for 1 h at 37 mC. Rosette inhibiting titres were defined by the abrupt decrease in number and size of rosettes. Rosettes were defined as cells associated with at least three erythrocytes (Dunster et al., 1994) .
Flow cytometry.
A persistently infected human Epstein-Barr virus (EBV)-transformed B cell line (WMPT ; gift from Dr Chain, University College Medical School, London, UK) and Ltk − H were used to test the reactivity of the MAbs with MV or MV-H protein by flow cytometry as described (Muller et al., 1995) . The FITC-conjugate alone on these cells, as well as MV-free WMPT cells and Ltk − F cells (a gift of Drs Wild and Beauverger ; Beauverger et al., 1993 Beauverger et al., , 1994 served as negative controls. In competition experiments between BH47 (IgG1) and BH216 (IgG2b), antibody binding was monitored with a subclass-specific FITC-labelled F(abh) # fragment of a goat anti-mouse IgG (Southern Biotechnology Associates).
Results

MAb specificities
After immunization with native MV, H-specific MAbs were obtained which in an ELISA based on biotinylated peptides mapped to amino acids 226-255 (Fig. 1) . The MAbs generated a typical band of 80 kDa under denaturing and reducing conditions by Western blot. They reacted both in a certified diagnostic ELISA (Enzygnost), and with immobilized MV purified from culture. In the latter assay, 50 %-saturating concentrations (S &! % ) were : BH1, 300 ng\ml ; BH47, 25 ng\ml (not shown) ; BH59, 20 ng\ml ; BH103, 160 ng\ml ; BH129, 30 ng\ml ( After intraperitoneal immunization and boosting with peptide H236-250 coupled to KLH (125 µg emulsified in complete\incomplete Freund's adjuvant) sera were obtained which reacted with the native MV as shown by flow cytometry on WMPT-MV cells and appropriate controls (Fig. 2E, F) .
These experiments demonstrate that the site associated with H236-250 and H241-255 is expressed on the surface of budding MV and recombinant H protein expressed in eukaryotic cells, while epitope 233-240 recognized by BH1 is perhaps not accessible or the reactivity of this MAb with the native protein is too weak.
Fine mapping
The site shared by peptides H236-250 and H241-255 was further defined using free truncation-analogues to inhibit Fig. 1 . Titration of affinity-purified MAbs BH1, BH59, BH103 and BH129 against an MV concentrate or the C-terminally biotinylated 15-mer peptides H236-250, H241-255 and H226-240 (only BH1) by ELISA. The titration curves against the peptides H231-245 or H246-260 were invariably negative with BH1 (not shown), BH59, BH103 and BH129 and fully overlapped with each other. The titration curves of BH47 (not shown) are similar to those of BH59. Peptides were selected on the basis of their reactivity in a Pepscan ELISA using biotinylated peptides covering the whole sequence of the MV-H protein (cf. Ziegler et al., 1996) . binding to H241-255 (Fig. 3) and H236-250 (data not shown). The 7-mer H244-250 competed up to five times more efficiently than the free 15-mer, while the 6-mer was a poor inhibitor. Similar results were obtained in competition assays with H236-250.
Functional activities of MAbs
For the following combined HI\HLI assay MAbs were titred against MV by ELISA and concentrations were normalized on the basis of their S &! % , corresponding to 1 ' IgG unit ' (cf. Fig. 1 and Table 1 ). When HLI and HI were concomitantly monitored in a combined assay, MAbs BH47, BH59 and BH129 inhibited haemolysis with an efficiency similar to haemagglutinin noose epitope (HNE) MAbs (BH6, BH21 and BH216) : 13-28 vs 8-24 IgG units (Table 1 ). Both groups of antibodies, however, markedly differed in their HI capacity : 500-5800 IgG subunits in comparison to 20-45 IgG subunits for the HNE MAbs (Table 1 ). In the case of the anti-HNE MAbs (BH6, BH21 and BH216), the IC &! % for lysis corresponds to the concentration for HI, while BH47, BH59 and BH129 show only residual HI activity, if any, at the concentration at which fusion inhibition is complete (Table 1) . Thus, in contrast to other H-specific MAbs, which inhibit HLI by blocking virus binding (HI + ), antibodies to site 241-250 inhibit HLI in a more direct way (HI − ). Also, 10 to 200 times higher concentrations of mAbs BH47 (4n2 µg\ml), BH59 (55 µg\ml), BH129 ( 23 µg\ml) are required, in comparison with HNE MAbs (0n25-0n43 µg\ml), in order to inhibit rosette formation with monkey erythrocytes and Ltk − H cells (data not shown).
Challenge/protection experiments
Single doses of purified BH47 (30-315 µg), BH59 (66-315 µg) and BH129 (66-315 µg) were injected intraperitoneally into 3-week-old CBA mice, which were challenged 2 days later by intracerebral injection of a lethal dose (12 500 TCID &! ) of CBA-adapted MV (derived from the CAM\RB strain ; a gift from Dr Liebert, Leipzig, Germany ; Liebert & ter Meulen, 1987) . These MAbs gave full protection even at the lowest concentrations tested, whereas MAb BH1 did not at 20 times this concentration (Fig. 4) .
Binding competition experiments between MAbs
To examine the topographical relationship between the linear site defined here and the HNE region (Ziegler et al., 1996) binding competition experiments were done on MV-infected cells (WMPT) and on Ltk − H cells using MAbs BH47 (IgG1) and BH216 (IgG2b) and IgG-subclass-specific FITC conjugates. Fig. 5 shows that binding of BH47 cannot be blocked by increasing concentrations of BH216 and BH216 cannot be blocked by BH47. No differences were found between WMPT and Ltk − H cells. The HI activity of BH216 is not modified by increasing concentrations of BH47, while the HLI activity of these two MAbs is additive (data not shown). Thus these two binding sites represent non-overlapping, independent domains, corresponding to different functional interfaces of the H protein.
Discussion
We developed a series of MV-specific MAbs which reacted with MV by Western blot under reducing conditions, neutralized the virus in vitro and protected mice against lethal challenge with a rodent-adapted MV strain. The antibodies were mapped to a linear site corresponding to two 15-mer peptides (H236-250 and H241-255) sharing the amino acids S#%"KRSELSQLS#&! of the MV-H protein. With truncationanalogues the site was further reduced to a 7-mer, S#%%ELSQLS#&!. Neutralizing epitopes have previously been located between amino acids 200 and 370 by studying the ' footprints ' of MAbs (I-41, 7-AG11, I-29 and I-44 ; Sheshberadaran & Payne, 1988) and the sequences of escape mutants (I-29, amino acids 313\314 ; 16DE6, three amino acid changes, one of which is amino acid 211 ; Sheshberadaran & Norrby, 1986 ; Hu et al., 1993 ; Liebert et al., 1994) . No such mutation has previously been found in the site described here. In a wild-type isolate (JM-1977) with mutations in position 211 and 243, reactivity of MAb 79-XV-V17 was lost (Tamin et al., 1994 ; Rota et al., 1992) . Studies with chimeric proteins have located the binding site of MAb 16-CD-11 to amino acids 211-291 (Hummel & Bellini, 1995) . Human late convalescent sera did not react with peptides representing this region and reactivity of mouse and rabbit hyperimmune sera was variable (Muller et al., 1993 ; .
Both H and F protein are required for fusion (Wild et al., 1991) . MV-H is responsible for cell tropism while MV-F is interchangeable with F protein of other morbilliviruses (Stern et al., 1995) . The primary function of the MV-H protein is to mediate virus attachment to CD46 of the target cell (Naniche et al., 1993) , which is followed by fusion of the viral envelope with the cell membrane (Gerlier et al., 1995) . This sequence of events may explain why H-specific antibodies, which inhibit haemagglutination (i.e. virus binding), also prevent haemolysis (i.e. fusion) indirectly. When HI MAbs were removed from the serum by adsorption with Tween-ether-treated MV (Norrby & Gollmar, 1975) , the remaining HLI activity was mostly MV-F specific. Also, MV-F-specific MAbs are typically HLI + and HI − . The MAbs corresponding to the site S#%%ELSQLS#&! are remarkable in that they are also HI − and HLI + , but they are MV-H specific. Another antibody (I-29) with these properties has been mapped to the epitope 309-318 (Ma$ kela$ et al., 1989 a) with critical amino acids in position 313\314 (Hu et al., 1993) . Such MAbs inhibit the functional cross-talk between the H and F proteins in a more direct way than HI + MAbs. Mechanisms of action may include the prevention of conformational or topographical rearrangements of the H protein or simply steric effects.
Data from escape mutants (Sheshberadaran & Norrby, 1986 ; Hu et al., 1993 ; Liebert et al., 1994) , even when complemented with MAb competition experiments (Carter et al., 1982 ; Ma$ kela$ et al., 1987) , cannot unequivocally define antibody-binding domains (Diamond et al., 1985 ; Parry et al., 1990) . Binding assays with chimeric and deletion homologues of the H protein do not normally have the sensitivity of those with short peptides (Hummel & Bellini, 1995) . Peptide mapping of epitopes may offer some advantages over other techniques, although it is normally restricted to a few sequential epitopes. Here, we show that MAbs binding to (HI − \HLI + ) site 244-250 are functionally different from those binding to (HI + \HLI + ) domain 381-400, recently described by us (Ziegler et al., 1996) . Moreover, the functionally distinct MAbs specific for the two sites bind to topographically non-overlapping domains. They seem to define two functionally and\or topographically distinct interfaces of the H protein, one of which is clearly not involved in the H\receptor interaction. An attractive interpretation of these observations would be that this interface is biased towards a functional and\or topographical interaction with the fusion protein. Fusion is dependent on the formation of the H\F\CD46 complex (Wild et al., 1991) , suggesting that fusion may be triggered by H\CD46 interaction (Lecouturier et al., 1996) . In this context it is interesting that Arg-243, which is directly adjacent to the epitope, is involved in downregulation of CD46 binding (Bartz et al., 1996 ; Lecouturier et al., 1996) . This could be indicative of a functional link between an H\receptor and an F\H interface.
N-Glycosylation has also been implicated in the cell fusion process (Malvoisin & Wild, 1994) . The S#%%ELSQLS#&! epitope is downstream of the cluster of glycosylation sites (amino acids 168, 187, 200, 215 and 238 ; Hu et al., 1994) . MAb BH1 reacts with peptides containing the sequence 233-240 but not with the MV-infected EBV-transformed cells or with a eukaryotically expressed recombinant H protein. Glycosylation in position 238 could be one explanation for this finding, although this site was thought not to be utilized, at least in some strains (Hu et al., 1994) .
Although the site of virus interactions with the simian or mouse brain receptor may differ from the site interacting with human CD46 (Naniche et al., 1993 ; Shibahara et al., 1994) , the mechanism of haemolysis of monkey erythrocytes and MV infection of human cells may call on similar interactions between the F and H protein. If this is the case, our findings suggest that prevention of H from functionally interacting with F inhibits virus infection both in vitro (by neutralization) and in vivo (by challenge\protection). Although expected, to the best of our knowledge, this has not been shown in vivo with any other HI − \HLI + H-specific MAb. It means that HI activity and protection are not necessarily linked as has been suggested (Giraudon & Wild, 1985) . Segregation of protection and HI activity of MAbs has been observed for other paramyxoviruses (Tsurudome et al., 1986 ; Piga et al., 1990) . Since the MAbs are of the IgG1 isotype, protection seems to be independent of complement fixation and FcγRI binding (Neuberger & Rajewsky, 1981 ; Ravetch & Kinet, 1991) , the most important effector mechanism in virus clearance (Ishizaka et al., 1995) .
Site 381-400 was referred to as HNE381-400 (Haemagglutinin Noose Epitope or Haemagglutinating and Neutralizing Epitope ; Ziegler et al., 1996) . To discriminate between epitopes involved in HI or not, epitope 244-250 could be referred to as NE244-250 (Neutralizing Epitope only).
The site described here is an attractive candidate to incorporate into a subunit vaccine. It is linear and its antigenicity and immunogenicity can be mimicked by short peptides. The experience with the killed MV vaccine facilitating atypical measles suggested that antibodies against the fusion protein are required for full protection Fulginiti et al., 1967) . Although antibodies against the site described here are H-specific, they exhibit the main properties (HI − , HLI + ) of F-specific antibodies. Two protective sequences of the F protein have been described (Steward et al., 1995 ; Obeid et al., 1995) , but whether in the absence of epitopes of the F protein, abundant antibodies against the NE epitope could potentially be sufficient to prevent atypical measles is a challenging question.
